Pharma Focus Asia
KP - Choose our fully recyclable blister films

Novel ZetaMet™ Technology Discovered for Metastatic Bone Cancers

Zetagen Therapeutics, discovered novel ZetaMet™ technology for the treatment of metastatic bone cancers. This technology is the first to suspend cancer inhibit pain, and regenerate bone.

ZetaMet™ technology was earlier known as ZetaFuse. It is a synthetic, small-molecule, inductive biologic technology introduced to target and resolve metastatic bone lesions which restricts the further growth of tumor growth and regenerating bone.

ZetaMet™ is a novel and patented molecular pathway. The small molecule dosage is delivered with a proprietary drug-eluting carrier to the affected area which stimulates cells for the healthy bone growth known as “osteoblasts” and the growth of cells with bone degradation called “osteoclasts”.

Bone metastases are often found among cancer patients and occur when cells from primary cancerous tumor relocate to the bone. During the process of relocation, it can cause bone damage known as osteolysis.  Osteolysis causes small holes inside the bone thereby weakening it and increasing the risk of breakage. These holes are known as lytic lesions.

US Food and Drug Administration (FDA) has approved ZetaMet™ KYNMOBI™ for the treatment of metastatic bone cancers.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024